BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16707376)

  • 21. Correlation between methylation profile of promoter cpg islands of seven metastasis-associated genes and their expression states in six cell lines of liver origin.
    Li JL; Fei Q; Yu J; Zhang HY; Wang P; Zhu JD
    Ai Zheng; 2004 Sep; 23(9):985-91. PubMed ID: 15363188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search.
    Moribe T; Iizuka N; Miura T; Stark M; Tamatsukuri S; Ishitsuka H; Hamamoto Y; Sakamoto K; Tamesa T; Oka M
    Int J Oncol; 2008 Nov; 33(5):949-58. PubMed ID: 18949357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing.
    Yau TO; Chan CY; Chan KL; Lee MF; Wong CM; Fan ST; Ng IO
    Oncogene; 2005 Feb; 24(9):1607-14. PubMed ID: 15580286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest.
    Gho JW; Ip WK; Chan KY; Law PT; Lai PB; Wong N
    Cancer Res; 2008 Aug; 68(16):6743-51. PubMed ID: 18701499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis.
    Kanai Y; Hui AM; Sun L; Ushijima S; Sakamoto M; Tsuda H; Hirohashi S
    Hepatology; 1999 Mar; 29(3):703-9. PubMed ID: 10051471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correlations of CpG island methylator phenotype and OPCML gene methylation to carcinogenesis of hepatocellular carcinoma].
    Liu WJ; Wang L; Wang JP; Li JQ; Zhang CQ; Zheng L; Yuan YF
    Ai Zheng; 2006 Jun; 25(6):696-700. PubMed ID: 16764763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas.
    Jin J; You H; Yu B; Deng Y; Tang N; Yao G; Shu H; Yang S; Qin W
    Biochem Biophys Res Commun; 2009 Jan; 379(1):86-91. PubMed ID: 19100240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan.
    Hsu LS; Lee HC; Chau GY; Yin PH; Chi CW; Lui WY
    Oncol Rep; 2006 Feb; 15(2):507-11. PubMed ID: 16391877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma.
    Lee HS; Kim BH; Cho NY; Yoo EJ; Choi M; Shin SH; Jang JJ; Suh KS; Kim YS; Kang GH
    Clin Cancer Res; 2009 Feb; 15(3):812-20. PubMed ID: 19188151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ARHI, as a novel suppressor of cell growth and downregulated in human hepatocellular carcinoma, could contribute to hepatocarcinogenesis.
    Huang J; Lin Y; Li L; Qing D; Teng XM; Zhang YL; Hu X; Hu Y; Yang P; Han ZG
    Mol Carcinog; 2009 Feb; 48(2):130-40. PubMed ID: 18612997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylation-related silencing of p14ARF gene correlates with telomerase activity and mRNA expression of human telomerase reverse transcriptase in hepatocellular carcinoma.
    Zhang C; Guo X; Zhang L; Lu Z; Ma N; Cheng Y; Shen F; Zhang B; Wu M; Wei L
    J Surg Oncol; 2008 Nov; 98(6):462-8. PubMed ID: 18683194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma.
    Park HJ; Yu E; Shim YH
    Cancer Lett; 2006 Feb; 233(2):271-8. PubMed ID: 15885882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma.
    Zhang C; Li Z; Cheng Y; Jia F; Li R; Wu M; Li K; Wei L
    Clin Cancer Res; 2007 Feb; 13(3):944-52. PubMed ID: 17289889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma.
    Sakai M; Hibi K; Kanazumi N; Nomoto S; Inoue S; Takeda S; Nakao A
    Hepatogastroenterology; 2005; 52(66):1854-7. PubMed ID: 16334792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of catalase by reactive oxygen species via hypermethylation of CpG island II on the catalase promoter.
    Min JY; Lim SO; Jung G
    FEBS Lett; 2010 Jun; 584(11):2427-32. PubMed ID: 20416298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.
    Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ
    Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma.
    Macheiner D; Heller G; Kappel S; Bichler C; Stättner S; Ziegler B; Kandioler D; Wrba F; Schulte-Hermann R; Zöchbauer-Müller S; Grasl-Kraupp B
    J Hepatol; 2006 Jul; 45(1):81-9. PubMed ID: 16516329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of Galectin-1 gene in human hepatocellular carcinoma involves methylation-sensitive complex formations at the transcriptional upstream and downstream elements.
    Kondoh N; Hada A; Ryo A; Shuda M; Arai M; Matsubara O; Kimura F; Wakatsuki T; Yamamoto M
    Int J Oncol; 2003 Dec; 23(6):1575-83. PubMed ID: 14612929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma.
    Shimizu D; Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Suenaga M; Inokawa Y; Hishida M; Takano N; Nishikawa Y; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Oncol Rep; 2014 Mar; 31(3):1305-13. PubMed ID: 24366000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.